iBio (IBIO) Current Assets (2011 - 2026)
iBio (IBIO) posted quarterly Current Assets of $77.3 million for Q1 2026, up 1174.77% year-over-year from $6.1 million in Q1 2025, and up 44.66% quarter-over-quarter from $53.4 million in Q4 2025.
iBio (IBIO) Current Assets (2011 - 2026) Analysis & Trends
iBio (IBIO) has reported Current Assets for 16 consecutive years, with $77.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 1174.77% year-over-year to $77.3 million; the TTM figure through Mar 2026 stood at $77.3 million (up 1174.77% YoY), while the FY2025 annual figure was $9.7 million, down 37.97% from the prior year.
- Current Assets improved to $77.3 million in Q1 2026 per IBIO's latest filing, from $53.4 million in the prior quarter.
- Across five years, Current Assets topped out at $77.3 million in Q1 2026 and bottomed at $6.1 million in Q1 2025.
- Historically, Current Assets has averaged $33.7 million across 5 years, with a median of $27.1 million in 2023.
- Annual changes were most pronounced in 2025 — Current Assets plunged 83.23% — and 2026, when it soared 1174.77%.
- iBio's Current Assets stood at $38.2 million in 2022, then tumbled by 48.48% to $19.7 million in 2023, then tumbled by 57.94% to $8.3 million in 2024, then jumped by 544.54% to $53.4 million in 2025, then surged by 44.66% to $77.3 million in 2026.
- Business Quant data shows IBIO's Current Assets at $77.3 million in Q1 2026, $53.4 million in Q4 2025, and $50.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | iBio | 175.21 Mn | 175.21 Mn | - | 77.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 77.25 Mn |
| Dec 31, 2025 | 53.40 Mn |
| Sep 30, 2025 | 50.80 Mn |
| Jun 30, 2025 | 9.72 Mn |
| Mar 31, 2025 | 6.06 Mn |
| Dec 31, 2024 | 8.29 Mn |
| Sep 30, 2024 | 11.70 Mn |
| Jun 30, 2024 | 15.67 Mn |
| Mar 31, 2024 | 36.14 Mn |
| Dec 31, 2023 | 19.70 Mn |
| Sep 30, 2023 | 23.02 Mn |
| Jun 30, 2023 | 26.26 Mn |
| Mar 31, 2023 | 27.09 Mn |
| Dec 31, 2022 | 38.24 Mn |
| Sep 30, 2022 | 63.57 Mn |
| Jun 30, 2022 | 45.07 Mn |
| Mar 31, 2022 | 60.32 Mn |
| Dec 31, 2021 | 67.50 Mn |
| Sep 30, 2021 | 89.82 Mn |
| Jun 30, 2021 | 104.60 Mn |